Search

Displaying results 1131 - 1140 of 4575 in total
  1. Drug

    Quemliclustat

    go.drugbank.com/drugs/DB19160
    Investigational

    Quemliclustat is under investigation in clinical trial NCT05329766 (A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal

  2. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated

  3. Drug

    Cefpodoxime

    go.drugbank.com/drugs/DB01416
    ApprovedInvestigationalVet approved

    Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

  4. Drug

    Voriconazole

    go.drugbank.com/drugs/DB00582
    ApprovedInvestigational

    [A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]

  5. Drug

    Mecobalamin

    go.drugbank.com/drugs/DB03614
    ApprovedInvestigational

    Mixtures: Vita-Pac, Genicin Vita-Q
  6. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...

  7. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]

  8. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  9. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

  10. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye -...